Home Oncorus

Oncorus

Out of service
IPO
Developer of Tumor Immunotherapy Platform
Basic
Enterprise Profile

Basic Information

Oncorus Develops Next-Generation Immunotherapy Platforms to Treat Cancer: Its oncolytic virus immunotherapy platform is designed to engineer viruses capable of entering tumor cells, replicating within them, and causing the tumor cells to burst. This process simultaneously activates the immune system to eliminate any remaining cancer cells. Currently, Oncorus is developing an oncolytic herpes simplex virus primarily targeting highly malignant and aggressive tumors such as glioblastoma multiforme (GBM).
Oncorus, Inc.
Cambridge,Massachusetts,United States of America
15~50 people
April 01, 2015
info@oncorus.com

Enterprise Profile

Industrial Sector
New Drug Development Manufacture of Biological Pharmaceutical Products
Technology
Gene Technology Microbial/Viral Technology
Concept
Tumor Therapeutic Products
Application Scenarios
Innovative Drugs Prescription Drug Nucleic Acid Drugs